Abstract:Abstract Recent next-generation sequencing experiments have brought success in identifying cancer genes that were highly frequently mutated in tumors. As genomic sequencing experiments continue to identify large numbers of novel cancer mutations, one big challenge will be distinguishing driver mutations from passenger mutations. Driver mutations are the ones that have a role in oncogenesis or in the cancer phenotype, whereas passenger mutations are co-traveler that accumulate through DNA replication but are irrelevant to tumor development. From statistical point of view, driver genes are defined as those for which the non-silent mutation rate is significantly greater than a background (or passenger) mutation rate estimated from silent mutations. Statistical methods are now actively being developed to attempt to assess functional significance of a mutated gene in cancer sequencing studies. However, embedding biological knowledge on mutational process in tumors into statistical models is not trivial. These biological considerations include length of protein coding regions, gene structure, transcript isoforms, difference in mutation types, variation in background mutation rates, redundancy of the genetic code, multiple mutations in one gene, and functional consequence of different tumor types. They have not yet been fully addressed by current methods and tools for identifying driver genes. Driver mutations could be either common or rare among tumors. Identification of rare driver mutations may pose a potential challenge. In addition, mutation in one member of a collection of functionally related genes may result in the same net effect, and/or mutations in certain genes may be observed less frequently if they play functional roles in later stages of tumor development. At the pathway level, the frequency of rare driver mutations is accumulated in that pathway which warrants sufficient detection power. Thus, there is an increasing interest in the identification of driver pathways in tumor formation and progression. To meet these challenges, we developed a tool-DrGaP for identify driver genes and pathways in cancer sequencing studies. We introduced the Poisson processes to model the random nature of somatic mutation under no selection pressure. The new model can handle the identification of both driver genes and pathways or any gene sets in the same statistical framework. The new tool provides several significant improvements and increased power over current existing methods through simulations. To illustrate its utility, we applied the DrGaP to analysis of a recent lung cancer sequencing study. The DrGaP identified a few novel driver genes that were missed by previous methods, demonstrating its high accuracy and sensitivity. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3971. doi:1538-7445.AM2012-3971

Adaptation of a mutual exclusivity framework to identify driver mutations within oncogenic pathways

The Discovery of Mutated Driver Pathways in Cancer: Models and Algorithms

Detection Of Driver Pathways Using Mutated Gene Network In Cancer

Abstract 3971: DrGaP: A Powerful Tool for Identifying Driver Genes and Pathways in Cancer Sequencing Studies

Deciphering oncogenic drivers: from single genes to integrated pathways.

Identifying mutual exclusivity across cancer genomes: computational approaches to discover genetic interaction and reveal tumor vulnerability.

A Robust Method for Identifying Mutated Driver Pathways in Cancer

An Integrated Framework for Identifying Mutated Driver Pathway and Cancer Progression.

Advancing cancer driver gene identification through an integrative network and pathway approach

Identification of Mutated Driver Pathways in Cancer Using a Multi-Objective Optimization Model

WeSME: uncovering mutual exclusivity of cancer drivers and beyond

Identification of driver modules in pan-cancer via coordinating coverage and exclusivity

An Entropy-Based Method for Identifying Mutual Exclusive Driver Genes in Cancer

Identification of Collaborative Driver Pathways in Breast Cancer

Characterization of Potential Driver Mutations Involved in Human Breast Cancer by Computational Approaches

An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer

Integrative Computational Framework, Dyscovr, Links Mutated Driver Genes to Expression Dysregulation Across 19 Cancer Types

Prediction of Driver Modules Via Balancing Exclusive Coverages of Mutations in Cancer Samples.

Identification of Cancer Driver Modules by Combining Network Functional and Topology Information.

CoPath: Discovering Cooperative Driver Pathways Using Greedy Mutual Exclusivity and Bi-Clustering.

A Model and Algorithm for Identifying Driver Pathways Based on Weighted Non-Binary Mutation Matrix